Brian Sullivan to present at upcoming investor conferences for Celcuity
MINNEAPOLIS, Sept. 01, 2026 /CourierPR/ -- Celcuity Inc., a biotechnology company focused on developing and commercializing targeted therapies for solid tumors, will have its CEO and co-founder, Brian Sullivan, participate in upcoming investor conferences. Sullivan will present at two major events, providing insights into the company's strategies and progress.
On Tuesday, September 8, 2026, Sullivan will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference, scheduled for 10:15 a.m. EDT. A live webcast of the session will be available via a dedicated weblink. Similarly, on Wednesday, September 9, 2026, Sullivan will join a fireside chat at Citi's 2026 Biopharma Back to School Summit, which will begin at 8:00 a.m. EDT. Both webcasts will also be accessible through the company’s website, with replays available shortly after the live sessions.
Celcuity, headquartered in Minneapolis, is committed to advancing targeted therapies for solid tumors. The company’s flagship product, REVTORPYK™ (gedatolisib), is a potent pan-PI3K and mTORC1/2 inhibitor designed to comprehensively block the PI3K pathway. This mechanism of action differentiates it from other therapies targeting PI3Kα, AKT, or mTORC1 alone. The approval of REVTORPYK was supported by positive results from the VIKTORIA-1 Phase 3 clinical trial, which evaluated the drug in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer. The trial supported FDA approval for REVTORPYK for use in patients without a PIK3CA mutation following progression on endocrine therapy.
VIKTORIA-2, an ongoing Phase 3 clinical trial, includes two independent studies, Study 1 and Study 2. Study 1 focuses on evaluating gedatolisib in combination with palbociclib and fulvestrant as a first-line treatment for endocrine-resistant HR+/HER2- advanced breast cancer. Study 2 assesses the same combination with letrozole as a first-line treatment for HR+/HER2- advanced breast cancer that is endocrine-sensitive. Additionally, Celcuity is conducting a Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide for patients with metastatic castration-resistant prostate cancer.